Phase 1 Study of Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke

ClinicalTrials.gov · TERMINATED

20 participants

Abstract

Stroke is the third leading cause of death in the United States and the leading cause of serious long-term disability. Approximately 50% of the 750,000 people affected by stroke each year have residual physical impairment. Treatment options for recovery are limited at this time. Sildenafil (Viagra) has demonstrated the capability of significantly improving recovery in several animal experiments of stroke. This study is aiming to establish the safety of treatment with sildenafil in people with stroke with the ultimate aim of testing its usefulness to improve recovery.

Conditions: Ischemic Stroke.

Primary outcome: The maximum tolerated dose and toxicity profile of sildenafil treatment in patients with subacute ischemic stroke..

Enrollment: 20 participants.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• ClinicalTrials.gov
• Publisher page

Related studies

• Drug repositioning: a brief overview Journal of Pharmacy and Pharmacology, 2020
• Cyclic nucleotide phosphodiesterases in Drosophila melanogaster Biochemical Journal, 2005
• Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation BMC Systems Biology, 2011
• Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions Applied Sciences, 2021
• In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease CNS & Neurological Disorders - Drug Targets, 2018
• Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments Pharmaceuticals, 2021

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free